Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Huang Chen

Showing results (121-130 of 183) with videos related to

Pageof 19
Sort By:
Neoplasia (New York, N.Y.)|November 28, 2022
A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancerShin-Yi Chung, Yu-Chan Chang, Dennis Shin-Shian Hsu, et al.
The Oncologist|June 29, 2026
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid TumorsApostolia Maria Tsimberidou, Darren Sigal, Anna Varghese, et al.
Medicine|December 4, 2015
Incidence of and Risk Factors for Tuberculosis (TB) in Gastric Cancer Patients in an Area Endemic for TB: A Nationwide Population-based Matched Cohort StudyWen-Liang Fang, Yi-Ping Hung, Chia-Jen Liu, et al.
Oncotarget|June 6, 2015
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialJack P Wang, Chen-Yi Wu, Yi-Cheng Yeh, et al.
Journal of Clinical Apheresis|February 13, 2007
A new model for predicting the timing of leukapheresis on the basis of CD34+ cell and hematopoietic progenitor cell levelsHao-Wei Teng, Liang-Tsai Hsiao, Shu-Chou Chaou, et al.
Oncotarget|December 10, 2016
Clinical relevance of cell-free DNA in gastrointestinal tract malignancyYuan-Tzu Lan, Ming-Huang Chen, Wen-Liang Fang, et al.
Journal of the Chinese Medical Association : JCMA|December 31, 2017
Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan populationHwa-Yen Chiu, Liang-Yu Lin, Wen-Chi Chou, et al.
Clinical & Translational Immunology|July 4, 2020
Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor responseYi-Ru Pan, Chiao-En Wu, Yu-Chao Wang, et al.
Journal of the Chinese Medical Association : JCMA|December 30, 2025
Adjuvant chemoradiotherapy for stage III gastric cancer: A differential role in R0 and non-R0 resectionYin-Che Wang, Nai-Jung Chiang, Yi-Ping Hung, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world studyWei-Ze Wong, Nai-Jung Chiang, Kuei-Chuan Lee, et al.
Pageof 19

Showing results (121-130 of 183) with videos related to

Sort By:
Pageof 19
Neoplasia (New York, N.Y.)|November 28, 2022
A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancerShin-Yi Chung, Yu-Chan Chang, Dennis Shin-Shian Hsu, et al.
The Oncologist|June 29, 2026
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid TumorsApostolia Maria Tsimberidou, Darren Sigal, Anna Varghese, et al.
Medicine|December 4, 2015
Incidence of and Risk Factors for Tuberculosis (TB) in Gastric Cancer Patients in an Area Endemic for TB: A Nationwide Population-based Matched Cohort StudyWen-Liang Fang, Yi-Ping Hung, Chia-Jen Liu, et al.
Oncotarget|June 6, 2015
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialJack P Wang, Chen-Yi Wu, Yi-Cheng Yeh, et al.
Journal of Clinical Apheresis|February 13, 2007
A new model for predicting the timing of leukapheresis on the basis of CD34+ cell and hematopoietic progenitor cell levelsHao-Wei Teng, Liang-Tsai Hsiao, Shu-Chou Chaou, et al.
Oncotarget|December 10, 2016
Clinical relevance of cell-free DNA in gastrointestinal tract malignancyYuan-Tzu Lan, Ming-Huang Chen, Wen-Liang Fang, et al.
Journal of the Chinese Medical Association : JCMA|December 31, 2017
Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan populationHwa-Yen Chiu, Liang-Yu Lin, Wen-Chi Chou, et al.
Clinical & Translational Immunology|July 4, 2020
Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor responseYi-Ru Pan, Chiao-En Wu, Yu-Chao Wang, et al.
Journal of the Chinese Medical Association : JCMA|December 30, 2025
Adjuvant chemoradiotherapy for stage III gastric cancer: A differential role in R0 and non-R0 resectionYin-Che Wang, Nai-Jung Chiang, Yi-Ping Hung, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world studyWei-Ze Wong, Nai-Jung Chiang, Kuei-Chuan Lee, et al.
Pageof 19